Cargando…

Idiosyncratic drug‐induced liver injury: A short review

Idiosyncratic drug‐induced liver injury (iDILI) is a rare adverse drug reaction that occasionally leads to acute liver failure or even death. An aging population that uses more drugs, a constant influx of newly developed drugs, and a growing risk from herbal and dietary supplements of uncertain qual...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Yo‐ichi, Imai, Katsunori, Mima, Kosuke, Nakagawa, Shigeki, Hashimoto, Daisuke, Chikamoto, Akira, Baba, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678908/
https://www.ncbi.nlm.nih.gov/pubmed/29404475
http://dx.doi.org/10.1002/hep4.1064
_version_ 1783277534759092224
author Yamashita, Yo‐ichi
Imai, Katsunori
Mima, Kosuke
Nakagawa, Shigeki
Hashimoto, Daisuke
Chikamoto, Akira
Baba, Hideo
author_facet Yamashita, Yo‐ichi
Imai, Katsunori
Mima, Kosuke
Nakagawa, Shigeki
Hashimoto, Daisuke
Chikamoto, Akira
Baba, Hideo
author_sort Yamashita, Yo‐ichi
collection PubMed
description Idiosyncratic drug‐induced liver injury (iDILI) is a rare adverse drug reaction that occasionally leads to acute liver failure or even death. An aging population that uses more drugs, a constant influx of newly developed drugs, and a growing risk from herbal and dietary supplements of uncertain quality can lead to an increase in iDILI. Antimicrobials, central nervous system agents, and herbal and dietary supplements are the most common causes of iDILI in developed countries. iDILI is still a diagnosis of exclusion, and thus careful history taking and thorough work‐ups for competing etiologies, such as acute viral hepatitis, autoimmune hepatitis, and others, are essential. The pathogenesis of iDILI is not clear and includes a mix of host reactions, drug metabolites, and environmental factors. Immediate cessation of the suspected offending drug is key to preventing or minimizing progressive damage. No definitive therapies for iDILI are available, and the treatments remain largely supportive. (Hepatology Communications 2017;1:494–500)
format Online
Article
Text
id pubmed-5678908
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56789082018-02-05 Idiosyncratic drug‐induced liver injury: A short review Yamashita, Yo‐ichi Imai, Katsunori Mima, Kosuke Nakagawa, Shigeki Hashimoto, Daisuke Chikamoto, Akira Baba, Hideo Hepatol Commun Review Articles Idiosyncratic drug‐induced liver injury (iDILI) is a rare adverse drug reaction that occasionally leads to acute liver failure or even death. An aging population that uses more drugs, a constant influx of newly developed drugs, and a growing risk from herbal and dietary supplements of uncertain quality can lead to an increase in iDILI. Antimicrobials, central nervous system agents, and herbal and dietary supplements are the most common causes of iDILI in developed countries. iDILI is still a diagnosis of exclusion, and thus careful history taking and thorough work‐ups for competing etiologies, such as acute viral hepatitis, autoimmune hepatitis, and others, are essential. The pathogenesis of iDILI is not clear and includes a mix of host reactions, drug metabolites, and environmental factors. Immediate cessation of the suspected offending drug is key to preventing or minimizing progressive damage. No definitive therapies for iDILI are available, and the treatments remain largely supportive. (Hepatology Communications 2017;1:494–500) John Wiley and Sons Inc. 2017-06-28 /pmc/articles/PMC5678908/ /pubmed/29404475 http://dx.doi.org/10.1002/hep4.1064 Text en © 2017 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Yamashita, Yo‐ichi
Imai, Katsunori
Mima, Kosuke
Nakagawa, Shigeki
Hashimoto, Daisuke
Chikamoto, Akira
Baba, Hideo
Idiosyncratic drug‐induced liver injury: A short review
title Idiosyncratic drug‐induced liver injury: A short review
title_full Idiosyncratic drug‐induced liver injury: A short review
title_fullStr Idiosyncratic drug‐induced liver injury: A short review
title_full_unstemmed Idiosyncratic drug‐induced liver injury: A short review
title_short Idiosyncratic drug‐induced liver injury: A short review
title_sort idiosyncratic drug‐induced liver injury: a short review
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678908/
https://www.ncbi.nlm.nih.gov/pubmed/29404475
http://dx.doi.org/10.1002/hep4.1064
work_keys_str_mv AT yamashitayoichi idiosyncraticdruginducedliverinjuryashortreview
AT imaikatsunori idiosyncraticdruginducedliverinjuryashortreview
AT mimakosuke idiosyncraticdruginducedliverinjuryashortreview
AT nakagawashigeki idiosyncraticdruginducedliverinjuryashortreview
AT hashimotodaisuke idiosyncraticdruginducedliverinjuryashortreview
AT chikamotoakira idiosyncraticdruginducedliverinjuryashortreview
AT babahideo idiosyncraticdruginducedliverinjuryashortreview